Where Will CRISPR Therapeutics Be in 5 Years?
Equities are unpredictable in the short run. How the market will behave in the next six to 12 months is anyone's guess. However, over more extended periods, of five years or more, things become much more (if not wholly) predictable. The market tends to reward companies based on financial results and an improving outlook.
Before investing in a stock, intending to hold it long term, it's critical to determine how the company is likely to perform on these fronts. With that in mind, let's look at a rising star in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP). How do the company's prospects look for the next half-decade?
CRISPR Therapeutics is a clinical-stage biotech, so it has no products on the market yet. Unsurprisingly, the company is consistently unprofitable, but its overall financial situation looks rather competitive when pitted against its similarly sized peers. CRISPR recorded $70 million in revenue in the second quarter, up from $150,000 a year ago.
Source Fool.com
